Author at Microdose

Floris Wolswijk

Floris is the founder of Blossom. He couldn’t find a place that explained the science of psychedelics in a way that most people could understand. He was missing a place that went beyond Google Scholar searches but was not as dense as an academic book. After not finding such a resource for psychedelics (as medicine), he founded Blossom in September 2019. Floris has a master’s degree (MSc) in Psychology (2008-2012) from the Erasmus University in Rotterdam, The Netherlands. After university, he co-founded a start-up in a different field. He fell in love with the psychedelics field through his first personal experiences with psychedelics and subsequently an encounter with the scientific literature. He hopes to play a small part in making psychedelics more widely available and used both in medicine and for self-development.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Science

1 Dec 2022

Psychedelic Research Round-up, by Blossom

By Floris Wolswijk

Science

22 Nov 2022

Psychedelic Research Round-Up, by Blossom

By Floris Wolswijk

Science

14 Oct 2022

Psychedelic Research Round-Up, by Blossom

By Floris Wolswijk

Science

16 Sep 2022

Psychedelic Research Round-Up, by Blossom

By Floris Wolswijk

Join Our Newsletter for Exclusive Updates, Stories, and More

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Floris is the founder of Blossom. He couldn’t find a place that explained the science of psychedelics in a way that most people could understand. He was missing a place that went beyond Google Scholar searches but was not as dense as an academic book. After not finding such a resource for psychedelics (as medicine), he founded Blossom in September 2019. Floris has a master’s degree (MSc) in Psychology (2008-2012) from the Erasmus University in Rotterdam, The Netherlands. After university, he co-founded a start-up in a different field. He fell in love with the psychedelics field through his first personal experiences with psychedelics and subsequently an encounter with the scientific literature. He hopes to play a small part in making psychedelics more widely available and used both in medicine and for self-development.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads